Determination of Serum Homocysteine and Hypersensitive C-reactive Protein and Their Correlation with Premature Coronary Heart Disease
Background: This study aims to investigate the correlation between premature coronary heart disease (pCHD) and both serum homocysteine (Hcy) and hypersensitive C-reactive protein (hs-CRP).
Methods: A total of 170 patients with pCHD were enrolled in this study from June 2014 to April 2016 (including 52 patients with stable angina pectoris [SAP], 70 patients with unstable angina pectoris [UAP], and 48 patients with acute myocardial infarction [AMI]), together with 105 healthy controls (CON) selected at the same period, to observe the changes of Hcy and hs-CRP in CHD patients and those with different types of CHD.
Results: The levels of serum Hcy and hs-CRP in group pCHD were significantly higher than in group CON (P < .05). The levels of Hcy and hs-CRP in group AMI were significantly higher than in group UAP and group SAP (P < .05). The changes of serum Hcy and hs-CRP were significantly higher in patients with multi-vascular lesions and dual-vascular lesions than in those with single-vascular lesion (P < .05).
Conclusion: The levels of serum Hcy and hs-CRP in CHD patients are positively correlated with the severity of CHD, which increase with the increase of lesion count. The combined detection of Hcy and hs-CRP can initially reflect the severity of coronary artery, thus better guiding treatment and predicting prognosis.
Buckley DI, Fu R, Freeman M, et al. 2009. C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the U.S. Preventive Services Task Force. Ann Intern Med 151:483-95.
Devaraj S, Singh U, Jialal I. 2009. The evolving role of C-reactive protein in atherothrombosis. Clin Chem 55:229-38.
Feng L, Nian S, Zhang S, et al. 2016. The associations between serum biomarkers and stenosis of the coronary arteries. Oncotarget 7:39231-40.
Gong X, Zou X, Liu L, et al. 2013. Prognostic value of inflammatory mediators in 1-year outcome of acute ischemic stroke with middle cerebral artery stenosis. Mediators Inflamm 2013:850714.
Hernández-Díaz Y, Tovilla-Zárate CA, Juárez-Rojop I, et al. 2015. The role of gene variants of the inflammatory markers CRP and TNF-α in cardiovascular heart disease: systematic review and meta-analysis. Int J Clin Exp Med 8:11958-84.
Holven KB, Aukrust P, Retterstol K, et al. 2006. Increased levels of C-reactive protein and interleukin-6 in hyperhomocysteinemic subjects. Scand J Clin Lab Invest 66:45-54.
Li T, Chen Y, Li J, et al. 2015. Serum homocysteine concentration is significantly associated with inflammatory/immune factors. PLoS One 10:e0138099.
Libby P, Okamoto Y, Rocha VZ, et al. 2010. Inflammation in atherosclerosis: transition from theory to practice. Circ J 74:213-20.
Liu C, Yang Y, Peng D, et al. 2015. Hyperhomocysteinemia as a metabolic disorder parameter is independently associated with the severity of coronary heart disease. Saudi Med J 36:839-46.
Liuzzo G, Biasucci LM, Gallimore JR, et al. 1994. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 331:417-24.
Men X, Li J, Zhang B, et al. 2013. Homocysteine and C-reactive protein associated with progression and prognosis of intracranial branch atheromatous disease. PLoS One 8:e73030.
Pang X, Liu J, Zhao J, et al. 2014. Homocysteine induces the expression of C-reactive protein via NMDAr-ROS-MAPK-NF-κB signal pathway in rat vascular smooth muscle cells. Atherosclerosis 236:73-81.
Pang X, Liu J, Li Y, et al. 2015. Emodin inhibits homocysteine-induced C-reactive protein generation in vascular smooth muscle cells by regulating PPARγ expression and ROS-ERK1/2/p38 signal pathway. PLoS One 10:e0131295.
Pietilä KO, Harmoinen AP, Jokiniitty J, et al. 1996. Serum C-reactive protein concentration in acute myocardial infarction and its relationship to mortality during 24 months of follow-up in patients under thrombolytic treatment. Eur Heart J 17:1345-9.
Plank F, Burghard P, Friedrich G, et al. 2016. Quantitative coronary CT angiography: absolute lumen sizing rather than % stenosis predicts hemodynamically relevant stenosis. Eur Radiol 26:3781-9.
Schroecksnadel K, Grammer TB, Boehm BO, et al. 2010. Total homocysteine in patients with angiographic coronary artery disease correlates with inflammation markers. Thromb Haemost 103:926-35.
Steed MM, Tyagi SC. 2011. Mechanisms of cardiovascular remodeling in hyperhomocysteinemia. Antioxid Redox Signal 15:1927-43.
Strang F, Schunkert H. 2014. C-reactive protein and coronary heart disease: all said—is not it? Mediators Inflamm 2014:757123.
Suleiman M, Aronson D, Reisner SA, et al. 2003. Admission C-reactive protein levels and 30-day mortality in patients with acute myocardial infarction. Am J Med 115:695-701.
Suleiman M, Khatib R, Agmon Y, et al. 2006. Early inflammation and risk of long-term development of heart failure and mortality in survivors of acute myocardial infarction predictive role of C-reactive protein. J Am Coll Cardiol 47:962-8.
Weber C, Noels H. 2011. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med 17:1410-22.
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).